In The News
May 23, 2018: Chiromics Announces Non-Opioid Pain Program (pdf)
Chiromics LLC announces it is open to discussing the broad strategic partnering of its PAM-MOR™ with interested companies. We envision a comprehensive and collaborative effort to develop first-in-class PAM-MOR™ drugs for registration against multiple unmet medical needs in the areas of pain and treatment for opioid abuse. For more information, please contact email@example.com.
November 9, 2012: Chiromics and GlaxoSmithKline Enter into Collaboration (pdf)
Chiromics LLC today announced a collaboration with GlaxoSmithKline (GSK) to discover novel classes of small molecules against certain biological targets.
November 9, 2012: Chiromics and Bristol-Myers Squibb Form Drug Discovery Strategic Alliance (pdf)
Chiromics LLC today announced a strategic research alliance with Bristol-Myers Squibb Company which includes grants of non-exclusive license for use of Chiromics' chemical compound library, exclusive license to a proprietary chemical compound collection, and a screening collaboration to discover and optimize novel classes of small molecules against multiple therapeutic targets.
January 10, 2012: Kadmon and Chiromics Announce Licensing Agreement for Ground-breaking Chemical Compounds Library (pdf)
Kadmon Corporation, LLC, and Chiromics LLC today announced that they have entered into an agreement under which Chiromics has granted Kadmon a non-exclusive license for use of Chiromics' chemical compound libraries for the discovery and development of pharmaceutical products.